17,261 trials
COVID-19, SARS-CoV-2
Primary: The Number and Proportion of Subjects With AEs, SAEs, MAAEs, AESIs. — 45; 17; 5; 2 Participants
Systemic Lupus Erythematosus
Primary: Safety and Tolerability as Assessed by Number of Participants With Treatment- Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) — 23; 24; 2; 2 Participants
Resectable Cholangiocarcinoma · Stage IB Intrahepatic Cholangiocarcinoma AJCC v8 · Stage II Intrahepatic Cholangiocarcinoma AJCC v8
Primary: Number of Participants Who Completed All Preoperative and Operative Therapy — 22 Participants
Anatomic Stage III Breast Cancer AJCC v8 · Anatomic Stage IV Breast Cancer AJCC v8 · Locally Advanced Breast Carcinoma
Primary: Number of Subject With Overall Response — 15; 3; 8 Participants
HIV/AIDS · Tuberculosis, Pulmonary
Primary: Number of Participants With Viral Suppression at Week 24 — 75; 40; 0; 0 Participants
Neuropathic Pain
Primary: Concertation-time Profile of Ondansetron in Plasma, Measured by the Area Under the Concentration-time Curve (AUC) — 0.89; 0.87 mg*hr/L — p=0.8651
Alcohol Use Disorder
Primary: Concentrations of Glx (i.e., Glutamate + Glutamine) — 18.76; 18.57 mmol/kg — p=0.33
Amyotrophic Lateral Sclerosis · ALS
Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) — 81 Participants
Alzheimer Disease
Primary: ROC AUCs (MCI/AD vs Cognitively Unimpaired (CU)) for Medial Temporal Lobe (MTL) UCB-J Distribution Volume Ratio (DVR) and Hippocampal Volume — 0.79; 0.81 probability…
Type 1 Diabetes · Obesity
Primary: Proportion of Adults With T1D Achieving Composite Outcome (CGM-measured Time in Range (TIR)>70% With Time Below Range (TBR) of <4% and Reduction in Body Weight by 5%) at…
Type 1 Diabetes Mellitus · Hypoglycemia · Hypoglycemia Unawareness
Primary: A1c </= 6.5% and no Severe Hypoglycemia — 0.667 Proportion of participants
Huntington Disease
Primary: Safety: Proportion of Patients With Treatment Emergent Adverse Events (TEAEs) Related to Study Drug — 2; 1; 3; 3 Participants
Sepsis, Severe · Septic Shock
Primary: Phase II - Primary Outcome - Change in Total Cholesterol (48 Hours - Enrollment) — 9; -10; 4; 2 mg/dL
COVID
Primary: Efficacy - PaO2/FiO2 Ratio — 227; 209; 155; 248 mmHg (rounded)
Mild to Moderate Alzheimer's Disease
Primary: Number of Study Participants With at Least One Mild, Moderate, or Severe Treatment Emergent Adverse Events (TEAEs) — 36; 42; 39; 19 Participants